Francesco Caiazza

Francesco Caiazza has a diverse and extensive work experience in the field of biomedical research. Francesco is currently working as a Senior Scientist II in Translational Medicine at CytomX Therapeutics since 2022. Prior to this role, they held multiple positions at various institutions.

From 2016 to 2022, Caiazza was associated with the University of California, San Francisco (UCSF). Francesco served as a Research Affiliate from January 2019 to June 2022, where they were involved in a collaboration between UCSF, University College Dublin (UCD), and Alaunus Biosciences. As a Postdoctoral Researcher from January 2017 to December 2018, they focused on the development of cancer-specific pro-drugs and prognostic biomarkers using a mass spectrometry-based approach. Additionally, from February 2016 to February 2017, they worked as a Visiting Research Scholar at UCSF, contributing to the same project.

In 2019, Caiazza joined Alaunus Biosciences as a Senior Scientist, where they worked until May 2022. During their time there, they likely contributed to the development of therapeutic products or technologies.

Before their time at UCSF and Alaunus Biosciences, Caiazza worked at the University College Dublin (UCD) from 2013 to 2016. Francesco held the position of research fellow in translational oncology, focusing on investigating resistance mechanisms to targeted chemotherapies in metastatic colorectal cancer.

Prior to their tenure at UCD, Caiazza worked as a Postdoctoral Research Scientist at the University College Dublin from November 2011 to July 2013. Their research primarily focused on investigating novel targeted therapies for triple negative breast cancer.

Caiazza began their postdoctoral career at the University of Rochester Medical Center from August 2010 to November 2011. Here, they contributed to studies on transcription-independent steroid-mediated molecular signaling using Xenopus laevis oocytes as a model.

Their earliest work experience can be traced back to the Royal College of Surgeons in Ireland, where they worked as a Post-graduate Student/Research Assistant from August 2006 to April 2010. In this role, they made significant contributions to the understanding of estrogen-induced signaling in breast cancer and its potential implications for therapeutic interventions.

Caiazza's educational background includes their time as a Graduate Student at the Università degli Studi Roma Tre from November 2004 to July 2006. Their research during this period focused on studying the signaling pathways activated by estrogen receptors in a human colon cancer cell line.

Overall, Francesco Caiazza has a broad range of experience in translational medicine, cancer research, and molecular signaling. Their work spans various institutions, highlighting their expertise in the field.

Francesco Caiazza's education history begins with a Master's Degree in Biology from Università degli studi Roma TRE, which they obtained from 1999 to 2006. Following this, they pursued a Doctor of Philosophy (Ph.D.) in biomedical science from the Royal College of Surgeons in Ireland, completing it from 2006 to 2009. Later on, they embarked on a Postdoctoral Fellowship in Pharmaceutical Chemistry at the University of California, San Francisco, which they pursued between 2016 and 2017.

In addition to their formal educational qualifications, Francesco has obtained two certifications from edX. In February 2014, they obtained an Honor Code Certificate for Fundamentals of Clinical Trials and another Honor Code Certificate for Health and Society, both from edX.